| 前收市價 | 0.2900 |
| 開市 | 0.3300 |
| 買盤 | 1.2100 |
| 賣出價 | 1.5200 |
| 拍板 | 127.00 |
| 到期日 | 2024-07-05 |
| 今日波幅 | 0.3300 - 1.6000 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 無 |
BenzingamRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame during the COVID-19 pandemic. The beauty of mRNA technology is that it opens the door to a more personalized and effective treatment as messenger RNA instructs the patient’s cells how to combat diseases like cancer. Moderna Inc (NASDAQ: MRNA) and Merck & Co (NYSE: MRK) joined forces to advance cancer treatment with an experimental mRNA vaccine, used in combination with Merck
BenzingaWhat's Going On With Merck Stock On Monday?
On Monday, Merck & Co Inc (NYSE:MRK) announced the notice of the mutual exercise of an option to convert the companies’ ongoing co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208) into an exclusive global license for Merck. As previously announced under the companies’ original co-development and co-commercialization agreement, each party was granted an option to convert the co-exclusive license into an exclusive global license for Merck. Also Read: FDA Declines To
BenzingaWhat's Going On With Merck Stock On Friday?
On Thursday, the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) unanimously voted to recommend Merck & Co Inc’s (NYSE:MRK) Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for adults 65 years of age and older. It is also commonly known as the pneumonia vaccine. Specifically, the ACIP voted to recommend a single dose of Capvaxive for: Adults 65 years and older who have not previously received a pneumococcal conjugate vaccine or wh
